BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 19, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

June 2, 2020

View Archived Issues

FDA clears IND application for first-in-human trial of IO-202

Read More

FDA approves Tauvid for PET imaging in patients being evaluated for AD

Read More

Phenotype detection platform screens for new PD drugs

Read More

Tumor types have distinct microbiomes

Read More

New alcohol risk genes in Caucasians

Read More

A series of benzimidazolones causing rapid degradation of BCL6 as potential therapeutics for DLBCL

Read More

New inhibitors of the minichromosomal maintenance protein with potential for the treatment of NSCLC

Read More

LMP2 inhibition shows therapeutic potential in AD by protecting against neuroinflammation

Read More

Edgewise Therapeutics presents new myosin inhibitors

Read More

New JAK-2 inhibitors identified at the Dana-Farber Cancer Institute

Read More

Rudong Ringene Pharmaceuticals patents PTPN11 inhibitors

Read More

New histone deacetylase inhibitors discovered at Merck & Co.

Read More

Genentech and Roche synthesize new RAS protein inhibitors

Read More

Novus reports topline phase IIa data on OP-0201 in acute otitis media

Read More

Gilead reports phase III data on remdesivir in moderate COVID-19 pneumonia

Read More

FDA clears Opko to begin phase II trial of Rayaldee for mild to moderate COVID-19

Read More

Ocugen discontinues phase III trial of OCU-300 for ocular graft-versus-host disease

Read More

Interim phase Ib data with ALRN-6924 show chemoprotective effect

Read More

Avelumab does not show activity in recurrent osteosarcoma trial

Read More

FDA approves Brilinta to reduce first heart attack in patients with coronary artery disease

Read More

Mesothelin-targeting CAR MCY-M11 appears to be safe in phase I trial

Read More

Nicox's NCX-470 enters phase III development

Read More

CTI enrolling patients in phase III PREVENT trial of pacritinib in severe COVID-19

Read More

Olokizumab obtains first approval in Russia

Read More

Phase III study of sulopenem in cUTI does not meet primary endpoint

Read More

FDA approves Taltz for active nonradiographic axial spondyloarthritis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Rare disease illustration

    Rare earth: Biomarin to use global reach post-$4.8B Amicus buy

    BioWorld
    Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing